Altria CEO says FDA review process is broken as company fights regulator in court
Altria chief criticizes FDA rules while defending lawsuit against the agency
Altria CEO Sal Mancuso said the US Food and Drug Administration's review process for nicotine products is too slow and has hurt his company's ability to compete. He spoke at the Fortune 500 Innovation Forum in Detroit on Monday, in a conversation with Fortune's Diane Brady.
Altria, which owns Marlboro and Black & Mild, sued the FDA in September through its subsidiaries Helix Innovations and NJOY. The company claims the agency's review process blocks newer nicotine products from reaching the market and is seeking to change it.
The main points from Mancuso's comments
- Mancuso said Altria's On! nicotine pouch brand is a key innovation, but regulation has slowed its growth.
- He said the company is "the underdog" in the pouch category against Philip Morris's Zyn, but intends to lead the category over the long term.
- He argued most harm from tobacco comes from combustion, not nicotine itself, and said correcting that perception is important.
- He said FDA reviews that should take six months have taken up to six years in some cases.
- He claimed illegal products, particularly from China, have taken market share while avoiding the standards legal products must meet.
What the lawsuit is about
Under the Premarket Tobacco Product Application process, the FDA is legally required to review new tobacco products before they go on sale. It must decide within 180 days whether a product benefits public health overall. Altria claims the FDA has missed that deadline, and that delays have kept newer On! products off shelves while foreign products fill stores.
Last month, US District Judge James Wesley Hendrix of the Northern District of Texas granted a joint request from the FDA and the plaintiffs to pause the litigation. The FDA has said it would consider revisions to the review process and new rules as the market changes.
Mancuso: 'The regulations are broken'
"Quite frankly, the regulations are broken," Mancuso said. "There's too much information. We still want a high standard, but it should be streamlined."
He also said agency guidance is not durable and can be changed immediately, and that Altria wants faster authorization so consumers have more product choices. He said Altria also sued because it wanted enforcement against illicit products, which he claimed are mislabeled as made in the USA and sold in vape shops.
"At the very least, it should be an even playing field, not a playing field where bad actors are in a better position than responsible companies like ours," he said.
Why this matters beyond tobacco
Mancuso compared the nicotine market to how cannabis is regulated in the United States. Cannabis is legal in half of US states but has no federal standard, which he called a "hodgepodge" of rules. His argument is that unclear or slow regulation can put compliant companies at a disadvantage against unregulated sellers.
What is confirmed and what is not
Confirmed from the source: the lawsuit was filed in September, the litigation is paused by court order, and the FDA has said it may revise its rules. Mancuso's statements about six-year delays, mislabeled imports, and Chinese products are his claims, reported at the forum and in the lawsuit. They are not independently confirmed in the source material.